Amy E. Juedes

Array ( [id] => 17761713 [patent_doc_number] => 20220235325 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => STIMULATION OF DENDRITIC CELL ACTIVITY BY HOMOTAURINE AND ANALOGUES THEREOF [patent_app_type] => utility [patent_app_number] => 17/585377 [patent_app_country] => US [patent_app_date] => 2022-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17585377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897896 [patent_doc_number] => 12275802 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Compositions and methods for immunotherapy [patent_app_type] => utility [patent_app_number] => 17/583117 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 82 [patent_no_of_words] => 26101 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067220 [patent_doc_number] => 20240101646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => SARS-COV-2 CORONAVIRUS ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/273625 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19051181 [patent_doc_number] => 20240093150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => IMPROVED T-CELLS FOR CANCER THERAPY USING AMINO ACID STARVATION PATHWAYS [patent_app_type] => utility [patent_app_number] => 18/263658 [patent_app_country] => US [patent_app_date] => 2022-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418499 [patent_doc_number] => 20240294622 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => NOVEL ANTI-GREMLIN1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/261834 [patent_app_country] => US [patent_app_date] => 2022-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719108 [patent_doc_number] => 20220211827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/576321 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720720 [patent_doc_number] => 20220213440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => DENDRITIC CELL IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/576597 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578807 [patent_doc_number] => 20220135662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => NOVEL USE OF REGULATORY T CELL-SPECIFIC SURFACE PROTEIN LRIG-1 [patent_app_type] => utility [patent_app_number] => 17/575039 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17575039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19001990 [patent_doc_number] => 20240066061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => A CXCR3+ CELL OR CELL PREPARATION FOR USE IN CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 18/261121 [patent_app_country] => US [patent_app_date] => 2022-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19431012 [patent_doc_number] => 20240299510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => ANTIBODY-GUIDED PCSK9-MIMICKING IMMUNOGENS LACKING 9-RESIDUE SEQUENCE OVERLAP WITH HUMAN PROTEINS [patent_app_type] => utility [patent_app_number] => 18/270436 [patent_app_country] => US [patent_app_date] => 2021-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22900 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462431 [patent_doc_number] => 20240316100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => ENGINEERED T CELLS [patent_app_type] => utility [patent_app_number] => 18/270261 [patent_app_country] => US [patent_app_date] => 2021-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111296 [patent_doc_number] => 20240123046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => IMMUNOGENIC COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/257814 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939665 [patent_doc_number] => 20240034804 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => ANTI-SIRPa ANTIBODY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/265777 [patent_app_country] => US [patent_app_date] => 2021-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083171 [patent_doc_number] => 20240109972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => ANTIBODY AND TAXANE COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 18/038818 [patent_app_country] => US [patent_app_date] => 2021-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921367 [patent_doc_number] => 20240024371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => TREATING DIABETES [patent_app_type] => utility [patent_app_number] => 18/255570 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879166 [patent_doc_number] => 20240002535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/253709 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861974 [patent_doc_number] => 20230416410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => BOVINE ANTIBODY VARIANTS [patent_app_type] => utility [patent_app_number] => 18/037514 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18037514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879128 [patent_doc_number] => 20240002497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => NAV1.7 BINDERS [patent_app_type] => utility [patent_app_number] => 18/252428 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609913 [patent_doc_number] => 20220152192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR) [patent_app_type] => utility [patent_app_number] => 17/454108 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17454108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548425 [patent_doc_number] => 20220119766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => EX VIVO GENERATION OF GAMMA DELTA FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/521113 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 264 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17521113 [rel_patent_id] =>[rel_patent_doc_number] =>)